CorMedix Inc.CRMDEarnings & Financial Report
CorMedix Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutic products for the prevention and treatment of infectious, inflammatory and cardiorenal diseases. Its lead candidate targets catheter-related bloodstream infections, serving critical care and chronic dialysis patient populations primarily across North America and European markets.
CRMD Q4 FY2025 Key Financial Metrics
Revenue
$128.6M
Gross Profit
$107.3M
Operating Profit
$59.1M
Net Profit
N/A
Gross Margin
83.4%
Operating Margin
46.0%
Net Margin
N/A
YoY Growth
N/A
EPS
$0.20
CorMedix Inc. Q4 FY2025 Financial Summary
CorMedix Inc. reported revenue of $128.6M for Q4 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $21.3M, operating expenses totaled $48.2M.
Key Financial Metrics
| Total Revenue | $128.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 83.4% |
| Operating Margin | 46.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
CorMedix Inc. Q4 FY2025 revenue of $128.6M breaks down across 5 segments, led by Acquisition Of Melinta at $52.9M (41.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Acquisition Of Melinta | $52.9M | 41.1% |
| Melinta Portfolio | $45.5M | 35.4% |
| Other | $18.6M | 14.5% |
| Contract Revenue | $7.4M | 5.7% |
| BARDA Agreement | $4.2M | 3.3% |
CorMedix Inc. Revenue by Segment — Quarterly Trend
CorMedix Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Acquisition Of Melinta and Melinta Portfolio) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Acquisition Of Melinta | $52.9M | — | — | — |
| Melinta Portfolio | $45.5M | — | — | — |
| Other | $18.6M | $2.3M | $23.2M | — |
| Contract Revenue | $7.4M | — | — | — |
| BARDA Agreement | $4.2M | $1.4M | — | — |
CorMedix Inc. Annual Revenue by Year
CorMedix Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $311.7M).
CorMedix Inc. Quarterly Revenue & Net Profit History
CorMedix Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $128.6M | — | N/A | N/A |
| Q3 FY2025 | $104.3M | +810.2% | $108.6M | 104.1% |
| Q2 FY2025 | $39.7M | +4829.4% | $19.8M | 49.9% |
| Q1 FY2025 | $39.1M | — | $20.6M | 52.8% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Revenue | $39.1M | $39.7M | $104.3M | $128.6M |
| YoY Growth | N/A | 4829.4% | 810.2% | N/A |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Assets | $149.6M | $252.6M | $750.9M | $826.1M |
| Liabilities | $34.7M | $32.0M | $376.7M | $420.8M |
| Equity | $114.9M | $220.6M | $374.1M | $405.3M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $19.7M | $30.0M | $30.9M | $94.5M |